Share Price Increase to $10.93

It has come to my attention that Edison ( research firm ) published a research report on the 23rd of July with an increased price target on Mesoblast to $10.93 from $10.51. In summary the main reasons for the increase in valuation are: 1) Change in the probability of success of PC - 300-IV in diabetic nephorapthy following the encouranging results from interim phase II trials - they are awaiting news on a possible accelerated approval process on the back of the positive data.
2) Celgene's cash injection and it's added benefits of having such a pharma in it's books (potential development/commercialisation partner). Conversely, it negatively affects the fair value per share on the increase number of shares, but overall a very large positive. and
3) As mentioned by the professor on his interviewed, Edison is also of the view of an imminent regulatory desicion in Japan for MSC-100-IV in acute graft vs host disease, which could prove to be a significant share price catalyst if approved.
Go Mesoblast.